Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remission

Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remission - ONTRACK

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000621

Enrollment

Registered

2007-02-28

Start date

2007-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimal change nephrotic syndrome

Interventions

Prednisolone (+), combination therapy (-) Prednisolone (+), combination therapy (+)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with minimal change nephrotic syndrome with first manifestation or relapse

Exclusion criteria

Exclusion criteria: 1) Renal dysfunction (Ccr under 30 ml/min) 2) Histry of taking immunosuppressant within one month 3) Patients with malignant disease 4) Malabsorption syndrome or epilepsy 5) Severe heart, liver, or pancreatic disaese 6) Active infectious disease 7) Pregnancy 8) Hypersensitivity to cyclosporin 9) Hypersensitivity to ARB 10) Patients with FSGS 11) Others

Design outcomes

Primary

Measure	Time frame
The number of relapse after initial treatment and the duration of remission before the relapse	—

Countries

Japan

Contacts

Public ContactHitoshi Sugiyama

Okayama University Graduate School, Okayama, Japan Department of Medicine and Clinical Science

sannai@cc.okayama-u.ac.jp086-235-7235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026